Nat Cancer: Innovative anti-cancer results, new nano-preparations for one-time treatment induced systemic immunity to cure tumors.

On August 10, 2020, Ron Weiss, Professor, Department of Bioengineering, MIT, Department of Materials Science and Engineering, and Department of Bioengineering, Howard Hughes Medical Research Institute, Darrell J. Irvine, who co-authored the paper with Dong Yizhou, a professor at Ohio State University's School of Pharmacy (Dr. Li Should-zhong of the Massachusetts Department of Bioengineering and the Koch Institute for Integrated Cancer Research is the first author of the paper), published an article in the journal Nature Cancer, in which the paper was published.
researchers have developed a new multi-functional nanomaterial that preclinical studies have shown can cure 50 square millimeters of melanoma and colon cancer with a cure rate of 60-80%.
the material is made up of lipids, which are encased in self-replicating RNA-coded IL-12.
great potential for immunotherapy for cancer, but all the steps required to activate cancer treatment are very difficult.
researchers used the new material to induce immune cell death (immunogenic cell death, ICD) in cancer cells, stimulating an inflammatory response at the site of the cancer and successfully activating endologious CD8T cells to remove the cancer.
In particular, the new material contains three key components: 1) liposomes to promote ICD; 2) self-replicating RNA to activate TLR3 signaling pathfles to stimulate inflammatory responses and further co-ordinate lipids to promote cancer cell death; and 3) self Copy RNA-coded IL-12, regulate immune cells in the cancer microenvironment, promote antigen-promoting cells to present cancer antigens released by dead cancer cells, thereby inducing the activation and differentiation of endogenetic anti-cancer-specific CD8T cells, which in turn eliminates cancer.
preclinical study data show that only one treatment is needed to remove 60-90% of melanoma and colon cancer.
for multiple tumors, only one treatment of one of the larger tumors can successfully cure tumors in other areas, the cure rate is close to 40%.
can also be very effective at suppressing lung metastasis that has already occurred.
further studies have shown that CD8 T cells are a key factor in curing tumors.
CD8 T cells can form long-term immune memory to prevent cancer recurrence.
the study showed that multifunction nanomaterials can activate multiple immunotherapy path paths at the same time, providing a variety of possibilities for immunotherapy for future cancers.
the nanomaterial's ease of preparation greatly improves the possibility of translational clinical research and application.
patent (US Patent 16/739,407) based on this study has been granted to Strand Thereapeutics (https://) for further clinical conversion.
.